Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-month, Multicenter, Randomized, Open-label Study to Investigate Efficacy and Safety of Concentration Controlled Everolimus With Reduced Dose Cyclosporine A Versus Mycophenolate Mofetil With Standard Dose Cyclosporine A in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids

Trial Profile

A 12-month, Multicenter, Randomized, Open-label Study to Investigate Efficacy and Safety of Concentration Controlled Everolimus With Reduced Dose Cyclosporine A Versus Mycophenolate Mofetil With Standard Dose Cyclosporine A in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 27 Sep 2017 Results of 24-month sub-analysis from this trial, presented at the 18th Congress of the European Society for Organ Transplantation.
    • 27 Sep 2017 Results of a subanalysis comparing the efficacy and safety of everolimus+reduced-dose cyclosporine (EVR+rCsA) vs mycophenolate mofetil+standard-dose cyclosporine (MMF+sCsA) regimens in a subpopulation of KTR with ≥3 HLA mismatches, presented at the 18th Congress of the European Society for Organ Transplantation
    • 03 May 2017 Results of subgroup analysis assessing renal function outcome in HLA mismatch groups (n=100) presented at the 2017 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top